Niki BioSolutions, Inc. (NIKI)
NASDAQ: NIKI · Real-Time Price · USD
7.53
-1.30 (-14.72%)
Jul 21, 2026, 12:16 PM EDT - Market open

Company Description

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.

Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.

The company also develops SACT-COV19, a repurposed small molecule, which is in a preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule, which is in a preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule, which is in a preclinical trial for the treatment of gram+ve bacterial infections.

The company was formerly known as Aptorum Group Limited and changed its name to Niki BioSolutions, Inc. in July 2026.

Niki BioSolutions, Inc. was incorporated in 2010 and is headquartered in Princeton, New Jersey. Niki BioSolutions, Inc. operates as a subsidiary of Jurchen Investment Corporation.

Niki BioSolutions, Inc.
CountryUnited States
Founded2010
IndustryBiotechnology
SectorHealthcare
Employees1
CEOChung Yuen Huen

Contact Details

Address:
116 Village Boulevard, Suite 200
Princeton, New Jersey 08540
United States
Phone609 951 2222
Websiteaptorumgroup.com

Stock Details

Ticker SymbolNIKI
ExchangeNASDAQ
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001734005
CUSIP Number653942102
ISIN NumberUS6539421023

Key Executives

NamePosition
Chung Yuen HuenChief Executive Officer
Kwok Kuen WongChief Financial Officer